← Human Trials & Peer-Reviewed Studies
Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease
Plain-language guide to PMID 33125080 (2021): double-blind randomized controlled trial study of IGF-1 LR3 and GHRH (Growth Hormone-Releasing Hormone) in 61 men, fatty liver & elevated liver enzymes.
Key Facts
- PMID
- 33125080
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Stanley TL et al. (12 authors)
- DOI
- 10.1210/clinem/dgaa792
What This Study Did, in Plain Language
What Was Tested
Researchers studied IGF-1 LR3 and GHRH (Growth Hormone-Releasing Hormone) in the context of fatty liver & elevated liver enzymes in this randomized controlled trial publication.
To assess relationships between hepatic expression of IGF1 and IGF-binding proteins (IGFBPs) and measures of glycemia and liver disease in adults with NAFLD.
Secondarily to assess effects of GH-releasing hormone (GHRH) on circulating IGFBPs.
Who Took Part
According to the abstract, 61 men were involved.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized and double-blind.
The men were allocated by chance, so the IGF-1 LR3 group and the comparison group should start out alike.
Blinding on both sides kept the men and researchers unaware of who received IGF-1 LR3.
Analysis of data from a randomized clinical trial of GHRH.
Two US academic medical centers.
What Was Measured
PubMed files the paper under topics including Blood Glucose, Gonadotropin-Releasing Hormone, Growth Hormone-Releasing Hormone, HIV, HIV Infections, Insulin-Like Growth Factor Binding Proteins and Insulin-Like Growth Factor I.
Author keywords: Nonalcoholic fatty liver disease (NAFLD), human immunodeficiency virus, insulin-like growth factor-1, insulin-like growth factor–binding proteins and nonalcoholic steatohepatitis (NASH).
What This Means in Plain Language
The paper is a randomized and double-blind study of IGF-1 LR3 and GHRH (Growth Hormone-Releasing Hormone) in 61 men in people with fatty liver & elevated liver enzymes.
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2021 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the IGF-1 LR3 compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, Fatty liver & elevated liver enzymes research.
Our Notes on the Compounds
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
Related Pages
- Fatty liver & elevated liver enzymes research
- IGF-1 LR3 in the library
- GHRH (Growth Hormone-Releasing Hormone) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.